文献速递分子诊断临床免疫质量管理与危急值

脑脊液外泌体miRNA作为神经退行性疾病生物标志物

Exosomal miRNA in cerebrospinal fluid as biomarkers for neurodegenerative disease.
PubMed 文献 · Clin Chim Acta · 2026-05-19

该综述评估脑脊液外泌体miRNA作为阿尔茨海默病、额颞叶痴呆、帕金森病、路易体痴呆和肌萎缩侧索硬化诊断标志物的现有证据,比较外泌体分离技术与RT-qPCR、微滴数字PCR和小RNA测序等检测平台,并分析分析前因素及组合面板的诊断性能,提出标准化需求以推动临床实验室验证。

要点

  • 脑脊液外泌体miRNA具有疾病特异性表达模式且耐RNase降解。
  • 分析前因素如采集方案、溶血污染、冻融循环和昼夜采样变异需标准化。
  • 外泌体miRNA与核心脑脊液蛋白组合可望提升鉴别诊断准确性。

核心结论

  • 脑脊液外泌体miRNA是有潜力的神经退行性疾病诊断标志物,但需分析前标准化和严格临床验证。

研究设计与样本

  • 综述评估脑脊液外泌体miRNA在阿尔茨海默病、额颞叶痴呆、帕金森病、路易体痴呆和肌萎缩侧索硬化中的诊断证据。
  • 比较外泌体分离技术及RT-qPCR、微滴数字PCR和小RNA测序等检测平台特征。

主要发现

  • 脑脊液外泌体miRNA由神经元、星形胶质细胞和小胶质细胞分泌,耐RNase降解且呈疾病特异性表达。
  • 现有核心脑脊液蛋白标志物如Aβ42/Aβ40比值、磷酸化tau和神经丝轻链在鉴别阿尔茨海默病与额颞叶痴呆或帕金森病与路易体痴呆时因蛋白谱重叠和免疫分析变异而受限。
  • 综述汇总了基于疾病分层的miRNA表达谱、组合面板的ROC性能及外泌体miRNA与核心脑脊液蛋白联合策略。

临床怎么用

  • 推动外泌体miRNA面板在严格验证的临床实验室实践中应用,需关注分析前标准化。

局限性

  • 分析前因素如采集方案、溶血污染、冻融循环和昼夜采样变异影响结果,需标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cerebrospinal fluid protein biomarkers, such as the Aβ42/Aβ40 ratio, phosphorylated tau, and neurofilament light chain, have significantly advanced the diagnostic process for Alzheimer's disease. Nonetheless, these biomarkers face challenges in effectively distinguishing Alzheimer's disease from frontotemporal dementia or Parkinson's disease from dementia with Lewy bodies. This limitation arises from overlapping protein profiles and the variability inherent in immunoassay techniques. A complementary class of analytes is exosomal microRNAs in cerebrospinal fluid, where these non-coding RNAs are secreted by neurons, astrocytes, and microglia, are resistant to RNase degradation, and have a disease-specific expression pattern. This review critically evaluates the existing evidence of cerebrospinal fluid exosomal miRNAs as diagnostic biomarkers in Alzheimer's disease, frontotemporal dementia, Parkinson's disease, dementia with Lewy bodies, and amyotrophic lateral sclerosis. Exosome isolation techniques and detection platform characteristics were compared using RT-qPCR, droplet digital PCR, and small RNA sequencing. Pre-analytical factors, such as collection protocols, hemolysis contamination, freeze-thaw cycling, and circadian sampling variation, were assessed. miRNA profiling data based on disease stratification, receiver operating characteristic performance of the combinatorial panel, and strategies combining exosomal miRNAs with core cerebrospinal fluid proteins were synthesized. This article brings together disease-specific miRNA signatures, pre-analytical standardization needs, and diagnostic accuracy analyses in a translational model to fill the literature gap and form the basis for developing exosomal miRNA panels for rigorously validated clinical laboratory practice.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Alamri MA, Afzal M, Pandey SN, et al. Exosomal miRNA in cerebrospinal fluid as biomarkers for neurodegenerative disease. Clin Chim Acta. 2026. PMID: 42162905. doi:10.1016/j.cca.2026.121094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。